News >

Melanoma Field Continues to Shift With Targeted Therapy, Immunotherapy Approvals

Caroline Seymour
Published: Thursday, Jul 26, 2018

Joseph Stilwill, MD

Joseph Stilwill, MD

A number of the findings in melanoma presented at the 2018 ASCO Annual Meeting were in the adjuvant setting, reporting benefits with BRAF/MEK inhibition as well as anti–PD-1 therapies, said Joseph Stilwill, MD, a medical oncologist at the Sarah Cannon Research Institute.

State of the Science Summit™, A Summer of Progress: Updates from ASCO 2018, Stilwill addressed recent advances in melanoma and the focus of research moving forward.

OncLive: What did you focus on in your presentation on melanoma?

Stilwill: The really exciting advances in melanoma over the last year [have been in the] adjuvant [setting], both in the BRAF-positive population as well as in the general population. BRAF and MEK inhibition, as well as anti–PD-1 therapy, have shown a significant benefit in the adjuvant setting and are less toxic than [previously approved] adjuvant therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication